In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Acetylon raises $15mm in Series B-2 funding from Celgene

Executive Summary

Acetylon Pharmaceuticals Inc. (histone deacetylase inhibitors) has brought in $15mm through an untranched purchase by Celgene Corp. of its Series B-2 preferred stock. The start-up most recently closed a three-tranche $28mm Series B round in August 2011 and, with this financing, brings its equity total to $50mm. Acetylon has an HDAC inhibitor, ACY1215, in Phase I/II for multiple myeloma. Celgene, which is also developing HDAC inhibitors for cancer such as the FDA-approved Istodax (romidepsin), receives no options or licensing rights to Acetylon’s technologies in exchange for the investment, its first in the company. Mark Alles, Celgene’s chief commercial officer, has been appointed as a non-voting observer to the Acetylon board.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register